On August 15, 2024, GSK plc reported a favorable Florida State Court ruling that excludes certain expert testimonies in the ongoing Zantac litigation, affirming that ranitidine does not pose a significant cancer risk. This ruling aligns with scientific consensus and supports GSK's ongoing defense against related claims.